drug
zovegalisib
Phase 3updated 3mo agoby $RLAY Relay Therapeutics, Inc.
Phase 3community read0 votes
all catalysts(0)
nothing on the calendar yet
News(3)
- STAT+: A new ranking of pharma companies by R&D performanceMaryland drug board to cap price of Ozempic, TrumpRx partners with Cuban, GoodRx, and more biotech newsstat · 3mo ago
- Relay drug shows early promise against rare blood vessel diseasesWhile early, the findings suggest the therapy could be superior to Novartis’ Vijoice at treating “vascular anomalies,” a cluster of chronic conditions with few available treatments.biopharma_dive · 3mo ago
- Relay's PI3Kα inhibitor clears efficacy bar in Phase 2 vascular anomalies studyRelay Therapeutics’ first data readout for zovegalisib in a rare genetic disease beat Wall Street expectations, expanding the PI3Kα inhibitor’s R&D prospects beyond breast cancer. The biotech on Tu…endpoints · 3mo ago
Data sources
last refreshed 23m ago
Found something off?
comments(0)
5-min edit window · permanent after that